Under the terms of the settlement, the New Jersey-based company would provide $92.5 million in cash and $180 million worth of naloxone nasal sprays to treat overdoses.
The settlement in principle accounts for New Jersey-based Amneal's role in fueling the national epidemic of opioid addictions and overdoses, New York and California said in separate statements.
On the heels of a new partnership announced earlier this week between the state of California and a pharmaceutical company to ...
Good morning, and welcome to the Amneal Pharmaceuticals First Quarter 2024 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony Dimeo.
With an agreement in hand from Amneal Pharmaceuticals, Illinois stands to get part of about $270 million in cash and opioid treatments.
BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $91.6 million in its first quarter. On a per-share basis, the Bridgewater, New ...
Amneal Pharmaceuticals reports significant revenue and EBITDA growth in Q1 2024, driven by new product launches and strong market performance.
California is partnering with a New Jersey-based pharmaceutical company to purchase a generic version of Narcan.
Q1 Non-GAAP EPS of $0.14 beats by $0.05. Revenue of $659M (+18.1% Y/Y) beats by $39.97M. Generics revenues increased 14% due ...